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David S. Allan,1 Sarah Takach,1 Susan Smith,2 Mindy Goldman2An HLA-matched sibling remains the optimal donor for most patients undergoing allogeneic hematopoietic
stem cell transplantation (HSCT). Marked declines in total fertility rates in Canada over the past 50 years will
lead to increasing numbers of patients without sibling donors well into the future. We retrieved transplanta-
tion data from aCanadian center and the Canadian Blood andMarrowTransplant Group and total fertility data
from the United Nations Department of Economic and Social Affairs. The mean age of adults with acute my-
elogenous leukemia (AML), who underwent transplantation at The Ottawa Hospital between 1995 and 2004,
was 416 12 years (n5 87). The chance of finding 1 or more HLA-matched sibling donors for a patient with
AML treated in 2002 is reflected by the total fertility rate in 1961 (average birth year for patients and sibling
donors). The sibling rate for 1961 is the total fertility rate–1.0, or 2.68. The chance of having 1 or more HLA-
matched sibling is 53.7% (1–chances of no matched sibling, or 1 - 0.752.68). In 2009, the chance of identifying
a matched sibling is only 37.1%, because of declining total fertility rates. Following this trend, this chancewill be
24.6% in 2014 and 16.6% in 2024. Greater reliance on alternative donors, such as umbilical cord blood (UCB)
and HLA-mismatched donors, can be anticipated. The issue of declining fertility rates appears to be regional,
and the impact on transplantation will be more pronounced in Canada than in other developed nations.
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An HLA-matched related sibling donor is the op-
timal donor for most patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT)
[1,2]. Recent results from several groups also have re-
ported favorable outcomes for some patients using un-
related HLA-matched donors identified through
international registries [3-5]. Alternative donors,
such as haploidentical transplants, HLA-mismatched
transplants, and umbilical cord blood (UCB), are
emerging as potential options, but these are associated
with greater risk and increased resource utilization
[6-11]. Alternative donors are typically reserved for1Blood and Marrow Transplant Program, The Ottawa
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6/j.bbmt.2009.07.007patients with more advanced disease or with particular
high-risk features.
The likelihood of successfully identifying a suitable
HLA-matched sibling donor increases with a greater
number of siblings. With the marked decline in total
fertility rates over the past 50 years in Canada [12], pa-
tients will have fewer siblings and thus have a lower
chance of finding at least one matched sibling donor
for many years into the future.
Acute myelogenous leukemia (AML) is currently
the most common indication for allogeneic HSCT in
Canada [13] and afflicts approximately 1 in 25,000
individuals [14]. Although many patients are older
or have concomitant medical problems that
preclude aggressive treatment, a significant proportio-
n of patients are eligible for allogeneic HSCT and
can be cured in part by the graft-versus-leukemia effect
[1-3].
In this article, we provide a quantitative model for
the anticipated increasing reliance on unrelated and
alternative donors for patients with AML undergoing
allogeneic transplantation as a direct result of the
declining total fertility rates in the Canadian popula-
tion. The problem appears to be uniquely Canadian
among developed nations with active transplantation
programs. We provide some discussion of potential
strategies to preserve transplantation options for
Canadian patients.
Table 1. Calculating the Chance of Identifying an HLA-
Matched Sibling Donor Depending on Donor’s Year of Birth
Donor/Patient
Birth Year
Average Birth
Rate, Actual
Sibling Rate,
Calculated
Chance of $ 1
HLA-Matched Sibling
Donor, Calculated*
1951-1955 3.65 2.65 53.3%
1956-1960 3.88 2.88 56.3%
1961-1965 3.68 2.68 53.7%
1966-1970 2.61 1.61 37.1%
1971-1975 1.98 0.98 24.6%
1976-1980 1.73 0.73 18.9%
1981-1985 1.63 0.63 16.6%
1986-1990 1.62 0.62 16.3%
1991-1995 1.69 0.69 18.0%
1996-2000 1.56 0.56 14.9%
2001-2005 1.52 0.52 13.9%
*Formula: 1 - (0.75)sibling rate.
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The database of the Blood & Marrow Transplant
Program at The Ottawa Hospital was searched to
retrieve basic demographic information about patients
undergoing allogeneic transplantation for AML
between 1995 and 2004. All patients provided consent
in accordance with the institutional research ethics
board guidelines on the anonymous use of patient
information for research purposes. Data on average
birth rates per female in Canada and other countries
were retrieved from the Population Division of the
Department of Economic and Social Affairs of the
UnitedNations Secretariat [12]. Information on trans-
plantations performed in Canada was retrieved from
the Canadian Blood and Marrow Transplant Group
registry [13]. Information on the searches performed
by the OneMatch Marrow and Stem Cell Network
was provided by Canadian Blood Services.RESULTS
Themean age (6 SD) of adults with AMLwho un-
derwent HSCT at our center between 1995 and 2004
was 41 6 12 years (n 5 87). We estimated the year of
birth using themean patient age. For patients undergo-
ing transplantation in 2002, for example, the average
year of birth was 1961. Based on the assumption that
patients and their siblings are on average the same
age, we were able to determine the number of siblings
for patients undergoing transplantation in any given
year. Because the birth rate in 1961 was 3.68 per female
(Figure 1), the sibling rate was 2.68. Siblings have an
approximately 25% chance of being HLA-identical
based on principles of haplotype segregation, ignoring
the minor contribution from DNA recombination
events. Thus, the expected number of HLA-matched
siblings for a patient undergoing transplantation in0
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Figure 1. Total fertility rate in Canada, 1926-2004 (average children
per female age 15-49 years in her lifetime). The 1926-1959 rates exclude
Newfoundland, Yukon, and the Northwest Territories, and the 1960-
1990 rates exclude Newfoundland. (Source: Statistics Canada, unpub-
lished data.)2002 was 0.25 2.685 0.67.Within any given family,
more than 1 sibling may be an appropriate match for
a patient. The chance of finding at least 1 matched sib-
ling is equal to 1 minus the chance of not finding any
matched siblings, or 0.75n, where n is the sibling rate.
Thus, for a family of 4 siblings, the chance of finding
at least 1 matched sibling would be 1 - 0.753, or 58%.
In 2002, the chance of finding at least 1matched sibling
donor was 53.7% (sibling rate, 2.68). For patients
undergoing transplantation in 2009, the average year
of birth for the donors is 1968 when the birth rate is
2.61 (sibling rate, 1.61), and the chance of having at
least one matched sibling donor is on average 37.1%.
By the year 2024, the expected chance of having at least
1 HLA-matched sibling declines to 16.6% (Table 1).
The reliance on unrelated and alternative donors
will increase dramatically in Canada because of the
marked drop in available matched sibling donors
over the coming 15 years. If we assume that similar
numbers of transplantations will be performed for
AML over the next 15 years, then we can model the
number of patients who will require an alternative
strategy to matched-sibling transplantation (Figure 2).
In 2002, 107 allogeneic HSCTs were performed in
Canada for adult AML using matched related donors0
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Figure 2. Projected decline in HLA-matched related transplantations
in adults with AML in Canada (dashed line) and the increasing
need for unrelated or alternative donors (solid line) if the number of
adults undergoing transplantation for AML were to remain stable at
150 annually.
Figure 3. International trends in total fertility rates, 1970-2007.
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plantation in first complete remission (CR1) or be-
yond, patients receiving peripheral blood stem cells
(PBSCs) and/or bone marrow (BM), and patients un-
dergoing a myeloablative (MA) or nonmyeloablative
(NMA) conditioning regimen. From our previous cal-
culations, the average chance of finding at least 1
matched sibling donor was 53.7% in 2002. If there
were similar patients eligible for transplantation but
without a sibling donor, then we estimate that an addi-
tional 92 patients were potential candidates for unre-
lated or alternative donor transplantation. A total of
43 transplantations were performed using unrelated
donors and none were performed using CB in 2002,
representing 47% of the predicted number of eligible
patients. The gap between the number of patients po-
tentially eligible for unrelated or alternative donor
transplantation and those actually undergoing trans-
plantation may reflect some patients for whom no do-
nor could be identified, or patients who may have
progressed during the longer period needed to identify
and confirm an unrelated donor. Moreover, unrelated
transplantation may have been deemed too risky for
some patients, even if they were candidates for
matched sibling transplantation. Details concerning
the reasons why patients did not proceed to transplan-
tation are not available. Based on the reduced numbers
of patients who will have matched sibling donors, we
expect that increasing numbers of patients will require
alternative therapies, which could includematched un-
related, CB, and mismatched donors (Table 1).
We estimated the success rate of finding matched
unrelated donors (MUD) for Canadian patients
through international registries by calculating the total
number of donor workups requested through theOne-
Match Marrow and Stem Cell Network of Canadian
Blood Services, which coordinates unrelated donor
searches for all Canadian transplantation centers. The
success rate in finding a suitable donor (as determined
by the transplantation center) was used to estimate
the combined utility of the international unrelated reg-
istries for Canadian patients. Between 2004 and 2009,
a total of 2674 donor workups were requested for
Canadian patients, and 1296 suitable donorswere iden-
tified (48.5%). In terms of variation among ethnic
groups, success in finding a suitable donor was most
likely for patients of East Indian descent (59.6% of 47
requests) and the lowest rates were observed in patients
who self-identified as black (24.5% of 53 requests) and
Chinese origin (14.3% of 14 total requests). The most
common ethnicity of patients requiring unrelated
donor workups was Caucasian (2058 workups re-
quested and 50.0% success in finding a suitable donor)
and other/unknown (263 requests and 49.8% success).
Of interest, the success rate in finding a suitable donor
for aboriginal Canadians was only slightly lower than
that of the overall group (42.4% success in 33 requests).We addressed whether declining total fertility
rates are particular to Canada by examining trends in
several developing countries during the period 1970-
2007. We found varying degrees of decline in total
fertility rates over the past 40 years in most countries
(Figure 3), although the United States has maintained
a stable rate of approximately 2.0, whereas France and
the United Kingdom have had stable total fertility
rates of approximately 1.8 since 1990, and Germany
and Italy have had stable fertility rates of approxi-
mately 1.5 since 1990. It appears that Canada and Ja-
pan are the only 2 developed nations that we
examined that have a similar trend of declining fertility
rates persisting beyond 1990.DISCUSSION
Our findings highlight the important impact of
declining fertility rates on the practice of allogeneic
HSCT in Canada. As the number of cases without a
matched sibling donor increases over the next 15 years,
there will be an increasing number of patients relying
on alternative donors, such as haploidentical, mis-
matched, and UCB donors.
Unrelated donor registries typically underrepre-
sent certain ethnic and minority groups, as we ob-
served in Canadian patients requiring donor searches
through the OneMatch Marrow and Stem Cell Net-
work. Overall, it appears that Canadian patients have
reasonable success in finding appropriate donors
through unrelated registries, although up to 50% of
patients still may not have a suitable donor. The utili-
zation rates of the National Marrow Donor Program
were estimated to be approximately 33% in a recent re-
port [15]. Moreover, donor registries must deal with
attrition and change of donor status, which can hinder
success in finding a matched donor in a timely manner.
It is likely that rates of successfully searching unrelated
donor registries will plateau and will remain chal-
lenged by rapid changes in global ethnic diversity.
The rate of finding a matched donor for Canadian
patients is substantially lower in specific population
subgroups, related to cultural and ethnic-specific
Biol Blood Marrow Transplant 15:1634-1637, 2009 1637Reduced Fertility Rates and BMT Donor Optionsfactors. We did not address data on changing fertility
rates in these subgroups of the Canadian population
in this study.
It remains uncertain whether the median age of
patients undergoing HSCT for AML will remain
stable. As the use of reduced-intensity conditioning
(RIC) regimens increases, we are likely to see an in-
crease in the median age of transplantation-eligible
patients. A separate analysis of the impact of chang-
ing fertility rates may be needed to better under-
stand the future impact on this older population of
patients with AML. It is likely that RUC transplan-
tation may delay the impact of reduced total fertility
rates.
Strategies that recognize the impact of changing
fertility rates in allogeneic HSCT are needed. In ad-
dition, alternative therapies for AML and other dis-
eases currently treated with blood and marrow
transplantation will become even more essential. In-
terestingly, the importance of changing fertility rates
varies in different countries [12], and different strate-
gies may be required to ensure an adequate supply of
matched donors in various jurisdictions. Other coun-
tries with well-developed HSCT programs may have
different demographics in terms of aging, immigra-
tion, and ethnic minority populations. It appears
that Canada faces challenges that are distinct from
the United States and some European countries in
this regard.
Potential strategies to ensure an adequate supply
of donors for allogeneic HSCT include UCB banking,
aggressive and novel recruitment strategies to unre-
lated donor registries, and successful development of
improved transplantation practices and leukemia care
reduce the need for HLA-matched donors.ACKNOWLEDGMENTS
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